论文部分内容阅读
“通过领先的医学探索和惊人的慈善行动帮助了很多人，这是我们的历史，我们的骄傲。”
美国礼来全球董事长、总裁兼首席执行官
John Lechleiter (李励达)博士如此对笔者说。
“We have helped a lot of people through advanced medical research and incredible philanthropic activities,” said John Lechleiter, chairman, president and CEO of Eli Lilly and Company, “This is our history and our pride.”
3月24日是世界防治结核病日。世界卫生组织(WHO)估计，每年全球因结核病而死亡的人数高达200~300余万人。据了解，中国现有超过500万名结核病活动性患者，而感染结核病菌的人数则超过5亿人，有超过80%的结核病病例发生在中国的农村地区，特别在中国的西部地区，发病率犹高。
为了阻止这种疾病的蔓延，美国礼来制药于2003年6月开始，启动了公司历史上规模最大的公益项目—“礼来耐多药结核病全球合作项目”。这是全球首个以抗击“耐多种药物型”结核病这一威胁世界、特别是发展中国家的公共卫生问题的综合性项目，旨在联合相关各方，为全球耐多药结核病患者提供质优价廉的药品，并寻找预防、治疗和监测这种疾病的最佳解决方案。
在没有硝烟的抗击结核病战斗中，美国礼来制药公司积极履行企业社会责任，践行着 “受之以鱼，莫若授之以渔”这句古老的中国谚语。
当今社会，企业在追求经济效益之外，履行社会责任已经成为全社会的共识。具有130多年历史的美国礼来公司一直致力于结核公益领域的投入，凭借拥有全球领先的抗结核武器—卷曲霉素，在全球抗击结核病领域，礼来冲在了最前面。
据李励达博士介绍，在礼来耐多药结核病全球合作项目的前8年（2003年-2011年），礼来制药在三大领域投入了1.35亿美元，在药品供应和向疾病高发国家的生产商转让药品制造技术方面投入7000万美元；在倡议活动、社区支持和医疗人员培训方面投入5000万美元；和在非盈利结核病药品研发项目方面投入1500万美元。 礼来耐多药结核病全球合作项目已经取得了巨大的成就，向全球七家公司转让制造技术，
培训了超过十万名医务人员，使他们能够更好地识别、诊断和治疗耐多药结核病，为患者和他们的家人提供护理和支持；为超过45,000家医院和诊所提供指导和防治工具箱。
2011年10月27日，礼来基金会再度出资3000万美元，用于该项目第三阶段的实施和运行。李励达博士指出：“虽然与抗击耐多药结核病所需的数以亿计的资金相比，我们的投入只是很小的一部分。我们无法独自应对这一全球挑战，但是，凭借我们独特的经验和能力，我们将继续发挥催化剂的重要作用。
据了解，这些资金将用于在2012年~2016年间加强两个重要领域的合作：为医务人员提供培训，其中包括专业医护人员，社区服务志愿者；改善安全有效、保证质量的二线药物的供应。 礼来耐多药结核病合作项目将继续与全球和本地的合作伙伴合作，重点关注中国、印度、俄罗斯和南非等四个疾病高发国家。
在中国，为抗击结核病与耐多药结核病，礼来积极实施公益行动。礼来公司中国区总裁艾博来先生提出，作为礼来耐多药项目的一个重要组成部分，2005年，礼来公司将卷曲霉素从原料到制剂的全套生产技术无偿转让给了浙江海正药业，并提供资金用于培训，以提升海正药业在管理、人员等方面的水准，确保其生产出具有国际一流品质而价格相对低廉的药品。这个合作使得海正药业成为除礼来公司以外，全球第二家利用礼来公司专利技术生产高品质卷曲霉素的公司。
艾博来总裁特别强调说，除了技术上的无偿转让，礼来还致力于公众健康教育。2009年，礼来公司牵手北京海淀高校，和北京市海淀区疾病预防控制中心共同开展了北京市海淀区高校结核与耐多药结核控制项目，这是目前中国最大规模的高校结核控制项目，通过各种活动，受益人数逾40万人。除了针对未来社会中坚的大学生人群的防治项目外，礼来还把温暖的目光转向了偏远的西部地区。
2009年9月，礼来公司以“传递希望，遏制结核”为主题的援助中国西部青海省耐多药结核病防治公益项目正式启动。通过这个项目，礼来将与青海卫生部门合作，培训各级医务人员，提高社区支持力度，推行病患倡导宣传并开展健康教育等多种形式的结核防治计划。
抗击结核与耐多药结核病只是礼来公司在履行企业社会责任中的一个缩影。李励达博士说，在礼来，每年都会举行一次“全球员工志愿者服务日”活动，分布在全球的上万名员工，在这一天会参与到社区的公益活动中去，他就是全身心投入其中的积极分子。
March 24 is the world Tuberculosis Day. The WHO estimates that as many as 2 to 3 million people die of tuberculosis each year. China alone has more than 5 million patients and over 500million people are infected. More than 80% of cases come from rural regions, especially in western China.
To prevent the spread of the disease, Eli Lilly kicked off the largest public-welfare project in its history in June 2003, the Lilly Global MDR-TB Partnership. This has been the first comprehensive program in the world to fight against MDR-TB, a threat to public health worldwide, especially in developing countries. The mission is to join forces with multiple parties to provide high-quality, affordable drugs to MDR-TB patients and find best solutions to prevent, treat and monitor the disease. Eli Lilly has spent $135million on this program.
In the smokeless battle against TB, Eli Lilly actively fulfills its social responsibility and exemplifies one of the best loved Chinese idioms – give him a fish and you feed him for a day; teach him fishing and feed him for a lifetime.
It is the consensus of the entire society that corporate needs to fulfill its social responsibility. Eli Lilly, an American business of 130 years has been dedicated to fighting TB. With its leading drug Capreomycin, Lilly has been at the frontline in the battle.
According to John Lechleiter, between 2003 and 2011, the first 8 years of the Lilly Global MDR-TB Partnership, Lily has spent $135million on three major initiatives: $70million on transferring manufacturing technology to high-prevalence countries; $50million on community support and medical practitioner training; $15million on non-for-profit drug R&D. The Lilly Global MDR-TB Partnership has achieved a lot, having transferred manufacturing technology to 7 companies and trained over 100,000 medical professionals, enabling them to better recognize, diagnose and treat MDR-TB, providing care and support to patients and their families, and offering guidance and medical kits to over 45,000 hospitals and clinics.
On November 27th, the Lily Foundation spent additional $30m for third-stage operations. “Billions are required to fight against MDR-TB, and Lily can only invest a small portion,” admitted John Lechleiter, “We cannot cope with such a global challenge on our own. But with our unique experience and capability, we can continue to be the catalyst.”
The fund will be used from 2012 to 2016 to strengthen collaboration in two important areas – training medical practitioners, including professionals and community volunteers; improving supply of safe, effective and good-quality second line drugs. The Lily Global MDR-TB Partnership will continue to work with global and local partners, with a focus on China, India, Russia and South Africa.
In China, Lilly gets very involved in public-welfare activities to fight against TB and MDR-TB. Eric Baclet, Lily China president said that in 2005, Lily transferred for free manufacturing technology of Capreomycin to Haizheng Pharmaceutical of Zhejian, from API to compound. Lily also provided capital for training to help Haizheng in management and staff competence, making sure that Haizheng produces world-class, relatively cheap drugs. Haizheng became the second company in the world to produce Capreomycin using Lily’s patents.
Eric Baclet emphasized that apart from free technology transfer, Lily is also dedicated to public-health education. In 2009, Lilly joined hands with universities in Haidian, Beijing and Haidian Disease Prevention and Control Centre to roll out a MDR-TB control program in universities in Haidian. This has been the largest fighting-against-TB project in Chinese universities, and more than 400,000 people benefited from it. Apart from college students, Lily also noticed the remote western regions.
In September 2009, Lily started a program to help MDR-TB resistance efforts in Qinghai. Lily works with health authorities in Qinghai, training medical practitioners, supporting communities and running various prevention and education programs. The fight against MDR-TB is only part of Eli Lilly’s CSR commitment. John Lechleiter said that at Eli Lilly, there is the “Global Staff Volunteer Day” every year. Tens of thousands employees worldwide participate in community public-welfare activities on that day, and he himself is proud to be an enthusiastic volunteer.
美国礼来全球董事长、总裁兼首席执行官
John Lechleiter (李励达)博士如此对笔者说。
“We have helped a lot of people through advanced medical research and incredible philanthropic activities,” said John Lechleiter, chairman, president and CEO of Eli Lilly and Company, “This is our history and our pride.”
3月24日是世界防治结核病日。世界卫生组织(WHO)估计，每年全球因结核病而死亡的人数高达200~300余万人。据了解，中国现有超过500万名结核病活动性患者，而感染结核病菌的人数则超过5亿人，有超过80%的结核病病例发生在中国的农村地区，特别在中国的西部地区，发病率犹高。
为了阻止这种疾病的蔓延，美国礼来制药于2003年6月开始，启动了公司历史上规模最大的公益项目—“礼来耐多药结核病全球合作项目”。这是全球首个以抗击“耐多种药物型”结核病这一威胁世界、特别是发展中国家的公共卫生问题的综合性项目，旨在联合相关各方，为全球耐多药结核病患者提供质优价廉的药品，并寻找预防、治疗和监测这种疾病的最佳解决方案。
在没有硝烟的抗击结核病战斗中，美国礼来制药公司积极履行企业社会责任，践行着 “受之以鱼，莫若授之以渔”这句古老的中国谚语。
当今社会，企业在追求经济效益之外，履行社会责任已经成为全社会的共识。具有130多年历史的美国礼来公司一直致力于结核公益领域的投入，凭借拥有全球领先的抗结核武器—卷曲霉素，在全球抗击结核病领域，礼来冲在了最前面。
据李励达博士介绍，在礼来耐多药结核病全球合作项目的前8年（2003年-2011年），礼来制药在三大领域投入了1.35亿美元，在药品供应和向疾病高发国家的生产商转让药品制造技术方面投入7000万美元；在倡议活动、社区支持和医疗人员培训方面投入5000万美元；和在非盈利结核病药品研发项目方面投入1500万美元。 礼来耐多药结核病全球合作项目已经取得了巨大的成就，向全球七家公司转让制造技术，
培训了超过十万名医务人员，使他们能够更好地识别、诊断和治疗耐多药结核病，为患者和他们的家人提供护理和支持；为超过45,000家医院和诊所提供指导和防治工具箱。
2011年10月27日，礼来基金会再度出资3000万美元，用于该项目第三阶段的实施和运行。李励达博士指出：“虽然与抗击耐多药结核病所需的数以亿计的资金相比，我们的投入只是很小的一部分。我们无法独自应对这一全球挑战，但是，凭借我们独特的经验和能力，我们将继续发挥催化剂的重要作用。
据了解，这些资金将用于在2012年~2016年间加强两个重要领域的合作：为医务人员提供培训，其中包括专业医护人员，社区服务志愿者；改善安全有效、保证质量的二线药物的供应。 礼来耐多药结核病合作项目将继续与全球和本地的合作伙伴合作，重点关注中国、印度、俄罗斯和南非等四个疾病高发国家。
在中国，为抗击结核病与耐多药结核病，礼来积极实施公益行动。礼来公司中国区总裁艾博来先生提出，作为礼来耐多药项目的一个重要组成部分，2005年，礼来公司将卷曲霉素从原料到制剂的全套生产技术无偿转让给了浙江海正药业，并提供资金用于培训，以提升海正药业在管理、人员等方面的水准，确保其生产出具有国际一流品质而价格相对低廉的药品。这个合作使得海正药业成为除礼来公司以外，全球第二家利用礼来公司专利技术生产高品质卷曲霉素的公司。
艾博来总裁特别强调说，除了技术上的无偿转让，礼来还致力于公众健康教育。2009年，礼来公司牵手北京海淀高校，和北京市海淀区疾病预防控制中心共同开展了北京市海淀区高校结核与耐多药结核控制项目，这是目前中国最大规模的高校结核控制项目，通过各种活动，受益人数逾40万人。除了针对未来社会中坚的大学生人群的防治项目外，礼来还把温暖的目光转向了偏远的西部地区。
2009年9月，礼来公司以“传递希望，遏制结核”为主题的援助中国西部青海省耐多药结核病防治公益项目正式启动。通过这个项目，礼来将与青海卫生部门合作，培训各级医务人员，提高社区支持力度，推行病患倡导宣传并开展健康教育等多种形式的结核防治计划。
抗击结核与耐多药结核病只是礼来公司在履行企业社会责任中的一个缩影。李励达博士说，在礼来，每年都会举行一次“全球员工志愿者服务日”活动，分布在全球的上万名员工，在这一天会参与到社区的公益活动中去，他就是全身心投入其中的积极分子。
March 24 is the world Tuberculosis Day. The WHO estimates that as many as 2 to 3 million people die of tuberculosis each year. China alone has more than 5 million patients and over 500million people are infected. More than 80% of cases come from rural regions, especially in western China.
To prevent the spread of the disease, Eli Lilly kicked off the largest public-welfare project in its history in June 2003, the Lilly Global MDR-TB Partnership. This has been the first comprehensive program in the world to fight against MDR-TB, a threat to public health worldwide, especially in developing countries. The mission is to join forces with multiple parties to provide high-quality, affordable drugs to MDR-TB patients and find best solutions to prevent, treat and monitor the disease. Eli Lilly has spent $135million on this program.
In the smokeless battle against TB, Eli Lilly actively fulfills its social responsibility and exemplifies one of the best loved Chinese idioms – give him a fish and you feed him for a day; teach him fishing and feed him for a lifetime.
It is the consensus of the entire society that corporate needs to fulfill its social responsibility. Eli Lilly, an American business of 130 years has been dedicated to fighting TB. With its leading drug Capreomycin, Lilly has been at the frontline in the battle.
According to John Lechleiter, between 2003 and 2011, the first 8 years of the Lilly Global MDR-TB Partnership, Lily has spent $135million on three major initiatives: $70million on transferring manufacturing technology to high-prevalence countries; $50million on community support and medical practitioner training; $15million on non-for-profit drug R&D. The Lilly Global MDR-TB Partnership has achieved a lot, having transferred manufacturing technology to 7 companies and trained over 100,000 medical professionals, enabling them to better recognize, diagnose and treat MDR-TB, providing care and support to patients and their families, and offering guidance and medical kits to over 45,000 hospitals and clinics.
On November 27th, the Lily Foundation spent additional $30m for third-stage operations. “Billions are required to fight against MDR-TB, and Lily can only invest a small portion,” admitted John Lechleiter, “We cannot cope with such a global challenge on our own. But with our unique experience and capability, we can continue to be the catalyst.”
The fund will be used from 2012 to 2016 to strengthen collaboration in two important areas – training medical practitioners, including professionals and community volunteers; improving supply of safe, effective and good-quality second line drugs. The Lily Global MDR-TB Partnership will continue to work with global and local partners, with a focus on China, India, Russia and South Africa.
In China, Lilly gets very involved in public-welfare activities to fight against TB and MDR-TB. Eric Baclet, Lily China president said that in 2005, Lily transferred for free manufacturing technology of Capreomycin to Haizheng Pharmaceutical of Zhejian, from API to compound. Lily also provided capital for training to help Haizheng in management and staff competence, making sure that Haizheng produces world-class, relatively cheap drugs. Haizheng became the second company in the world to produce Capreomycin using Lily’s patents.
Eric Baclet emphasized that apart from free technology transfer, Lily is also dedicated to public-health education. In 2009, Lilly joined hands with universities in Haidian, Beijing and Haidian Disease Prevention and Control Centre to roll out a MDR-TB control program in universities in Haidian. This has been the largest fighting-against-TB project in Chinese universities, and more than 400,000 people benefited from it. Apart from college students, Lily also noticed the remote western regions.
In September 2009, Lily started a program to help MDR-TB resistance efforts in Qinghai. Lily works with health authorities in Qinghai, training medical practitioners, supporting communities and running various prevention and education programs. The fight against MDR-TB is only part of Eli Lilly’s CSR commitment. John Lechleiter said that at Eli Lilly, there is the “Global Staff Volunteer Day” every year. Tens of thousands employees worldwide participate in community public-welfare activities on that day, and he himself is proud to be an enthusiastic volunteer.